secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001628280-23-012415
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics terminates $50M at-the-market equity offering with Cantor and RBC
--------------------------------------------------------------------------------

- On April 20, 2023, Avalo delivered notice to Cantor and RBC to terminate the Sales Agreement, effective by April 30, 2023.
- The agreement allowed sale of up to $50M of common stock through the sales agents.
- No termination penalties are associated with the termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023012415/0001628280-23-012415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023012415/avtx-20230420.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-012415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer